NCT04072354: A reported trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04072354 |
|---|---|
| Title | A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 17, 2019 |
| Completion date | May 12, 2023 |
| Required reporting date | May 12, 2026, midnight |
| Actual reporting date | May 4, 2026 |
| Date last checked at ClinicalTrials.gov | July 3, 2026 |
| Days late | None |